MDT-AP-0402
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 48
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- C6
- umap1_2d
- 3.933521188
- umap2_2d
- 7.085866446
- umap1_3d
- 2.95367732
- umap2_3d
- -1.413829273
- umap3_3d
- -4.766207043
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.280
- HEME_METABOLISM+0.190
- OXIDATIVE_PHOSPHORYLATION+0.180
- NOTCH_SIGNALING+0.170
- ADIPOGENESIS+0.130
- WNT_BETA_CATENIN_SIGNALING+0.130
- DNA_REPAIR+0.120
- PI3K_AKT_MTOR_SIGNALING+0.100
- PEROXISOME+0.050
- HEDGEHOG_SIGNALING+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- ALLOGRAFT_REJECTION-0.490
- INFLAMMATORY_RESPONSE-0.490
- ANGIOGENESIS-0.450
- E2F_TARGETS-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- G2M_CHECKPOINT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.380
- ANDROGEN_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1354 | Med | Medulloblastoma | 0.924 |
| 2 | MDT-AP-0364 | Med | Medulloblastoma | 0.920 |
| 3 | MDT-AP-1357 | Med | Medulloblastoma | 0.920 |
| 4 | MDT-AP-2017 | Med | Medulloblastoma | 0.906 |
| 5 | MDT-AP-0381 | Med | Medulloblastoma | 0.895 |
| 6 | MDT-AP-2588 | Med | Medulloblastoma | 0.893 |
| 7 | MDT-AP-1341 | Med | Medulloblastoma | 0.888 |
| 8 | BS_GE2RVZE6 | Med | Medulloblastoma | 0.875 |
| 9 | MDT-AP-0119 | Med | Medulloblastoma | 0.871 |
| 10 | MDT-AP-3253 | Med | Medulloblastoma | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |